Neffy nasal epinephrine is now available without a prescription in Canada
ALK Canada says its 2 mg epinephrine nasal spray can now be obtained without a prescription where one was previously required. Schedule II access involves a pharmacist.
In this article & details
ALK Canada announced on Nov. 9 that Neffy, its 2 mg epinephrine nasal spray for the emergency treatment of severe allergic reactions, is available without a prescription in Canadian jurisdictions where one had previously been required. The change follows a national scheduling decision that puts the spray behind the pharmacy counter where Schedule II applies.
Updated Nov. 16, 2026, to report ALK Canada’s nonprescription availability announcement.
From an August launch to behind-the-counter access
Health Canada authorized Neffy in April 2026, and ALK announced the Canadian market launch in August. That launch brought the nasal product to pharmacies. The November change concerns how people obtain it. The National Association of Pharmacy Regulatory Authorities (NAPRA) finalized its Schedule II recommendation effective Nov. 5, after a consultation on the interim September recommendation.
NAPRA’s listing applies to nasal epinephrine indicated for emergency treatment of anaphylactic reactions. Under Schedule II, the medicine is kept where customers cannot select it themselves, and a pharmacist is involved in the sale. ALK says local scheduling rules may differ and directs people to their provincial or territorial pharmacy regulator for the rules in their jurisdiction.
The announcement applies to the 2 mg nasal spray
The Canadian product monograph specifies the authorized population for the 2 mg spray: adults and children weighing at least 30 kg. The announcement extends access to a non-injectable option within that indication. It does not extend the indication to children below that weight.
The company’s notice describes access without a prescription. It does not announce a change to public or private plan coverage or guarantee that a pharmacy has stock.
References
- Neffy now available without a prescription — ALK Canada, Availability announcement, Nov. 9, 2026 (accessed Nov 8, 2026)
- Final recommendation for nasal epinephrine — NAPRA, Effective Nov. 5, 2026 (accessed Nov 8, 2026)
- Epinephrine nasal spray: Schedule II listing — NAPRA, National Drug Schedules entry (accessed Nov 8, 2026)
- Neffy 2 mg Canadian product monograph — Health Canada, Authorized indication and patient information
- Canadian market launch of Neffy — ALK, Company release, Aug. 5, 2026
Discussion
0 commentsJoin the discussion. Anyone can read the comments. To comment, log in or create a free individual account.
No comments yet.